Hydroxychloroquine in Mild Graves' Orbitopathy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Hydroxychloroquine in Mild Graves' Orbitopathy — Stella

Home/Graves Ophthalmopathy/

View on ClinicalTrials.gov

Recruiting

Back to Graves Ophthalmopathy trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

Taiwan

National Taiwan University Hospital, Hsin-Chu branch, Hsinchu

National Taiwan University Hospital, Taipei

Key details

Phase

Post-approval study

Sponsor

National Taiwan University Hospital

Enrollment target

~108 participants

Started

March 2022

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.